By Rob Curran
Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials.
The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter.
The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease.
"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease," said Lantheus' medical director, Luca Passamonti.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
April 30, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。